LNTH Lantheus Holdings, Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
13:06
Aug 04
Aug 04
Wall Street analysts issued a broad batch of upgrades, downgrades.
Wall Street analysts issued a broad batch of upgrades, downgrades, and coverage initiations across multiple stocks, with notable price target changes including NKE cut to $40 and REPL raised to $17.
16:30
Aug 03
Aug 03
Curium agrees to acquire Lantheus Holdings in a roughly eight billion dollar take-private.
Curium agrees to acquire Lantheus Holdings in a roughly eight billion dollar take-private transaction.
12:11
Aug 03
Aug 03
US pre-market movers report includes merger talks between AstraZeneca and Bristol-Myers.
US pre-market movers report includes merger talks between AstraZeneca and Bristol-Myers, a GME convertible exchange, a Curium-Lantheus deal, BABA's AI launch, and multiple analyst rating changes across several stocks.
00:30
Jul 28
Jul 28
Curium is in advanced talks to acquire radiopharma company Lantheus in a deal that could be.
Curium is in advanced talks to acquire radiopharma company Lantheus in a deal that could be announced in the coming days according to sources.
15:27
Mar 09
Mar 09
FDA approved a new formulation for PYLARIFY to increase batch sizes, and NEURACEQ sales recently jumped from $20 million to $31 million quarter-over-quarter. The new PYLARIFY formulation will expand geographic reach, while the growing US dementia crisis will turn NEURACEQ into a blockbuster product, driving significant revenue. Buy LNTH as an undervalued biotech play with a proven sales team and highly successful medical imaging products. Slower than expected adoption of NEURACEQ, competition from other imaging agents, or unforeseen regulatory hurdles.
HIGH
About LNTH Analyst Coverage
Buzzberg tracks LNTH (Lantheus Holdings, Inc.) across 4 sources. 1 bullish vs 0 bearish calls from 4 analysts. Sentiment: predominantly bullish (20%). 5 total trade ideas tracked. Latest voices: DeItaone, Bloomberg, Newsquawk.